Apogee Therapeutics, Inc. (APGE)
134.96
0.00 (0.00%)
USD |
NASDAQ |
Aug 28, 16:00
134.96
0.00 (0.00%)
After-Hours: 20:00
Apogee Therapeutics Cash from Operations (Quarterly) : -71.38M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -71.38M |
| March 31, 2026 | -55.57M |
| December 31, 2025 | -62.69M |
| September 30, 2025 | -54.26M |
| June 30, 2025 | -62.03M |
| March 31, 2025 | -48.48M |
| December 31, 2024 | -67.71M |
| September 30, 2024 | -42.52M |
| June 30, 2024 | -29.30M |
| Date | Value |
|---|---|
| March 31, 2024 | -31.64M |
| December 31, 2023 | -29.75M |
| September 30, 2023 | -19.88M |
| June 30, 2023 | -14.57M |
| March 31, 2023 | -10.56M |
| December 31, 2022 | -9.189M |
| September 30, 2022 | -7.238M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | -77.27M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Intellia Therapeutics, Inc. | -83.11M |
| Revolution Medicines, Inc. | -387.32M |
| Erasca, Inc. | -27.27M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -381.86M |
| Cash from Financing (Quarterly) | 107.02M |
| Free Cash Flow | -243.96M |
| Free Cash Flow Per Share (Quarterly) | -0.9461 |
| Free Cash Flow to Equity (Quarterly) | -169.40M |
| Free Cash Flow to Firm (Quarterly) | -69.80M |
| Free Cash Flow Yield | -2.66% |